Ensayo clínico de RO7276389 en monoterapia y en combinación con cobimetinib en participantes con tumores sólidos avanzados

THIS RESEARCH STUDY (WHICH IS ALSO KNOWN AS A CLINICAL TRIAL) OF A DRUG CALLED RO7276389, IS BEING DEVELOPED FOR THE POSSIBLE TREATMENT OF AN AGGRESSIVE SOLID TUMOR TYPE, SUCH AS SKIN CANCER (MELANOMA). THIS STUDY INVOLVES RESEARCH. AN EXPERIMENTAL DRUG CALLED RO7276389 WILL BE TESTED AND WILL BE ADMINISTERED ALONE (SEPARATELY) OR IN COMBINATION WITH COBIMETINIB. THE MAIN OBJECTIVES ARE AS FOLLOWS: - TO EVALUATE THE SAFETY OF DIFFERENT DOSES OF RO7276389, GIVEN ALONE OR IN COMBINATION WITH COBIMETINIB, TO FIND OUT WHAT SIDE EFFECTS THE STUDY TREATMENT HAS. - COLLECT DATA TO LEARN WHETHER RO7276389, GIVEN ALONE OR IN COMBINATION WITH COBIMETINIB, IS EFFECTIVE AGAINST SOLID TUMORS OR BRAF-MUTATED MELANOMA. - TO TEST HOW RO7276389, GIVEN ALONE OR IN COMBINATION WITH COBIMETINIB, IS DISTRIBUTED IN AND ELIMINATED FROM THE BODY.